{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:41:35Z","timestamp":1789170095746,"version":"build-2803163510"},"reference-count":44,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>This study reviews and evaluates the national drug formulary system used to improve patient access to new drugs by making reimbursement decisions for new drugs as part of the South Korean national health insurance system. The national health insurance utilizes three methods for improving patient access to costly drugs: risk-sharing agreements, designation of essential drugs, and a waiver of cost-effectiveness analysis. Patients want reimbursement for new drugs to be processed quickly to improve their access to these drugs, whereas payers are careful about listing them given the associated financial burden and the uncertainty in cost-effectiveness. However, pharmaceutical companies are advocating for drug prices above certain thresholds to maintain global pricing strategies, cover the costs of drug development, and fund future investments into research and development. The South Korean government is expected to develop policies that will improve patient access to drugs with unmet needs for broadening health insurance coverage. Simultaneously, the designing of post-listing management methods is warranted for effectively managing the financial resources of the national health insurance system.<\/jats:p>","DOI":"10.3390\/ijerph16020288","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T03:08:22Z","timestamp":1548126502000},"page":"288","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System"],"prefix":"10.3390","volume":"16","author":[{"given":"Seung-Lai","family":"Yoo","sequence":"first","affiliation":[{"name":"College of Pharmacy, Chung-Ang University, Seoul 06974, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Chung-Ang University, Seoul 06974, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Mi","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Chung-Ang University, Seoul 06974, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Gu","family":"Kang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Chung-Ang University, Seoul 06974, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yoon","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Chung-Ang University, Seoul 06974, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-8037","authenticated-orcid":false,"given":"Jong Hyuk","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Engineering, Hoseo University, Asan 31499, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Churl","family":"Suh","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Chung-Ang University, Seoul 06974, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.healthpol.2014.05.005","article-title":"Managed entry agreements for pharmaceuticals in Australia","volume":"117","author":"Vitry","year":"2014","journal-title":"Health Policy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/CEOR.S39634","article-title":"Medical technology as a key driver of rising health expenditure: Disentangling the relationship","volume":"5","author":"Sorenson","year":"2013","journal-title":"Clin. Outcomes Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.healthpol.2018.01.006","article-title":"Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in central and eastern european countries","volume":"122","author":"Rotar","year":"2018","journal-title":"Health Policy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.socscimed.2014.11.003","article-title":"Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in belgium, england, the netherlands and sweden","volume":"124","author":"Ferrario","year":"2015","journal-title":"Soc. Sci. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jval.2011.12.013","article-title":"Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions","volume":"15","author":"Walker","year":"2012","journal-title":"Value Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/11535580-000000000-00000","article-title":"Financial effects of pharmaceutical price regulation on r&d spending by eu versus us firms","volume":"28","author":"Golec","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fphar.2016.00305","article-title":"Payers\u2019 views of the changes arising through the possible adoption of adaptive pathways","volume":"7","author":"Ermisch","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3322\/caac.21443","article-title":"The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.healthpol.2017.09.005","article-title":"A review of international coverage and pricing strategies for personalized medicine and orphan drugs","volume":"121","author":"Degtiar","year":"2017","journal-title":"Health Policy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/ten.teb.2016.0291","article-title":"Evaluating the past, pesent, and future of regenerative medicine: A global view","volume":"23","author":"Ronfard","year":"2017","journal-title":"Tissue Eng. Part B Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Garrison, L.P., and Towse, A. (2017). Value-based pricing and reimbursement in personalised healthcare: Introduction to the basic health economics. J. Pers. Med., 7.","DOI":"10.3390\/jpm7030010"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/medlaw\/fww009","article-title":"Reimbursement of cell-based regenerative therapy in the uk and france","volume":"24","author":"Mahalatchimy","year":"2016","journal-title":"Med. Law Rev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Adamski, J., Godman, B., Ofierska-Sujkowska, G., Osi\u0144ska, B., Herholz, H., Wendykowska, K., Laius, O., Jan, S., Sermet, C., and Zara, C. (2010). Risk sharing arrangements for pharmaceuticals: Potential considerations and recommendations for european payers. BMC Health Serv. Res., 10.","DOI":"10.1186\/1472-6963-10-153"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1017\/S0266462310001297","article-title":"What principles should govern the use of managed entry agreements?","volume":"27","author":"Klemp","year":"2011","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jval.2012.02.004","article-title":"Australian managed entry scheme: A new manageable process for the reimbursement of new medicines?","volume":"15","author":"Wonder","year":"2012","journal-title":"Value Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1377\/hlthaff.2011.1309","article-title":"Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries","volume":"31","author":"Neumann","year":"2012","journal-title":"Health Aff. (Millwood)"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e0172971","DOI":"10.1371\/journal.pone.0172971","article-title":"Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in australia","volume":"12","author":"Chim","year":"2017","journal-title":"PLoS ONE"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1215\/03616878-2373166","article-title":"Can the nice \u201cend-of-life premium\u201d be given a coherent ethical justification?","volume":"38","author":"Cookson","year":"2013","journal-title":"J. Health Politcs Policy Law"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1634\/theoncologist.2010-S1-36","article-title":"Ethical and value issues in insurance coverage for cancer treatment","volume":"15","author":"Brock","year":"2010","journal-title":"Oncologist"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/annonc\/mdx110","article-title":"Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the nhs cancer drugs fund","volume":"28","author":"Aggarwal","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jval.2016.04.001","article-title":"Did it matter that the cancer drugs fund was not nice? A retrospective review","volume":"19","author":"Dixon","year":"2016","journal-title":"Value Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1071\/AH16194","article-title":"Funding therapies for rare diseases: An ethical dilemma with a potential solution","volume":"42","author":"Taylor","year":"2018","journal-title":"Aust. Health Rev."},{"key":"ref_23","first-page":"525","article-title":"Comparative study on the system of rare medicine by country","volume":"33","author":"Sylvia","year":"2013","journal-title":"Health Soc. Welf. Rev."},{"key":"ref_24","unstructured":"Ministry of Health and Welfare (2006). Policy Report: Drug Expenditure Optimization System in National Health Insurance Services."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.healthpol.2016.03.013","article-title":"Eight-year experience of using hta in drug reimbursement: South korea","volume":"120","author":"Bae","year":"2016","journal-title":"Health Policy"},{"key":"ref_26","unstructured":"Ministry of Health and Welfare (2014). Policy Report: A Study on the Improvement of Drug Price System for the Improvement of Accessibility of New Products."},{"key":"ref_27","unstructured":"OECD (2017). Health at a Glance 2017, OECD."},{"key":"ref_28","unstructured":"National Health Insurance Service (2017). Ppri Pharma Profile Report: Korean Pharmaceutical Pricing and Repayment Policies, National Health Insurance Service."},{"key":"ref_29","unstructured":"National Health Insurance Service (2012). Policy Report: A Study on the Introduction of Risk Sharing Contract, National Health Insurance Service."},{"key":"ref_30","unstructured":"Health Insurance Review Assessment Service (2017). Hira Notification: Detailed Evaluation Criteria for New Drugs Subject to Negotiation, Health Insurance Review Assessment Service."},{"key":"ref_31","unstructured":"Korean Pharmaceutical Manufacturers Association (2016). Kpma Policy Report: Korean Pharmaceutical Manufacturers Association, Korean Pharmaceutical Manufacturers Association."},{"key":"ref_32","unstructured":"Health Insurance Review Assessment Service (2018, November 30). List of Reimbursable Drugs. Available online: https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA030014050000."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.3390\/ijerph110707304","article-title":"The impact of out-of-pocket payments on health care inequity: The case of national health insurance in south korea","volume":"11","author":"Lee","year":"2014","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_34","unstructured":"Korea Institute for Health Social Affairs (2010). Policy Report: Policy Measures to Enhance Access to Drugs for Rare Diseases, Korea Institute for Health Social Affairs."},{"key":"ref_35","unstructured":"Korean Research-based Pharmaceutical Industry Association (2016). A Study on the Improvement of Drug Price System for the Improvement of Pharmaceutical Industry and the Improvement of Patient Access, Korea Institute for Health Social Affairs."},{"key":"ref_36","unstructured":"Korea Institute for Health Social Affairs (2015). Policy Report: A Study on the Rationalization of Drug Price Management System, Korea Institute for Health Social Affairs."},{"key":"ref_37","unstructured":"Korea Institute for Health Social Affairs (2014). Policy Report: The Problems and Improvement of the Payment System, Korea Institute for Health Social Affairs."},{"key":"ref_38","unstructured":"Ministry of Health and Welfare (2018). A Proposal for the Reform of the Drug Price System to Strengthen Health Insurance Coverage (Moon Care)."},{"key":"ref_39","unstructured":"Health Insurance Policy Institute (2017). Policy Report: A Study on the Health Insurance High-Cost Medicine, Health Insurance Policy Institute."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jval.2017.12.016","article-title":"Use and misuse of cost-effectiveness analysis thresholds in low- and middle-income countries: Trends in cost-per daly studies","volume":"21","author":"Leech","year":"2018","journal-title":"Value Health"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jval.2018.01.017","article-title":"Comparing the icers in medicine reimbursement submissions to nice and pbac-does the presence of an explicit threshold affect the icer proposed?","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health"},{"key":"ref_42","unstructured":"National Health Insurance Service (2013). A Study on the Improvement of Drug Price Negotiation and Drug Price Management System, National Health Insurance Service."},{"key":"ref_43","unstructured":"National Health Insurance Service (2013). Policy Report: A Study on the Promotion of Transparency in Price Negotiation, National Health Insurance Service."},{"key":"ref_44","unstructured":"Health Insurance Policy Institute (2012). Policy Report: A Study on the Establishment of Roadmap for Systematic Management of Health Insurance Pharmaceuticals, Health Insurance Policy Institute."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/2\/288\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:27:36Z","timestamp":1760185656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/2\/288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1]]}},"alternative-id":["ijerph16020288"],"URL":"https:\/\/doi.org\/10.3390\/ijerph16020288","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,21]]}}}